Proteasome inhibitor RE-sensitizing molecules for treatment of refractory multiple myeloma
Ended Project Grant Awarded Last action
- Award ID
- R42CA213488
- Recipient
-
Leukogene Therapeutics Inc. UEI DDD1BU62TM94
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,764,695
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- South Carolina, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $7,509 | |
| Amendment | -$82,056 | |
| Amendment | -$82,056 | |
| Amendment | -$82,056 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $1,015,871 | |
| Amendment | $3,353 | |
| Original award | $984,129 |
Quick answers
Who received award R42CA213488?
R42CA213488 was awarded to Leukogene Therapeutics Inc. by National Cancer Institute (National Institutes of Health) on September 22, 2016.
How much is award R42CA213488 worth?
$1,764,695 has been obligated on R42CA213488.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award